{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:14:52Z","timestamp":1778771692901,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>5-fluorocytosine is a pyrimidine and a fluorinated cytosine analog mainly used as an antifungal agent. It is a precursor of 5-fluorouracil, which possesses anticancer properties. To reduce systemic toxicity of 5-fluorouracil during chemotherapy, 5- fluorocytosine can be used as a targeted anticancer agent. Expression of cytosine deaminase by a viral vector within a tumor allows targeted chemotherapy by converting 5-fluorocytosine into the cytotoxic chemotherapeutic agent 5-fluorouracil. However, little is known about the tolerance of 5-fluorocytosine in dogs after prolonged administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In three healthy Beagle dogs receiving 100\u00a0mg\/kg of 5-fluorocytosine twice daily for 14 days by oral route, non-compartmental pharmacokinetics revealed a terminal elimination half-life of 164.5\u2009\u00b1\u200922.5\u00a0min at day 1 and of 179.2\u2009\u00b1\u200911.5\u00a0min, after 7 days of administration. Clearance was significantly decreased between day 1 and day 7 with 0.386\u2009\u00b1\u20090.031 and 0.322\u2009\u00b1\u20090.027 ml\/min\/kg, respectively. Maximal plasma concentration values were below 100\u00a0\u00b5g\/ml, which is considered within the therapeutic margin for human patients. 5-fluorouracil plasma concentration was below the limit of detection at all time points. The main adverse events consisted of depigmented, ulcerated, exudative, and crusty cutaneous lesions 10 to 13 days after beginning 5-fluorocytosine administration. The lesions were localized to the nasal planum, the lips, the eyelids, and the scrotum. Histological analyses were consistent with a cutaneous lupoid drug reaction. Complete healing was observed 15 to 21 days after cessation of 5-fluorocytosine. No biochemical or hematological adverse events were noticed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Long term administration of 5-fluorocytosine was associated with cutaneous toxicity in healthy dogs. It suggests that pharmacotherapy should be adjusted to reduce the toxicity of 5-fluorocytosine in targeted chemotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-021-02927-5","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T13:02:57Z","timestamp":1624280577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs"],"prefix":"10.1186","volume":"17","author":[{"given":"J\u00e9r\u00e9my","family":"B\u00e9guin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kohlhauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Laloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Degorce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baptiste","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Qu\u00e9m\u00e9neur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Erbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Klonjkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Maurey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"2927_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/0003-4819-86-3-319","volume":"86","author":"JE Bennett","year":"1977","unstructured":"Bennett JE. Flucytosine. Ann Intern Med. 1977;86:319.","journal-title":"Ann Intern Med"},{"key":"2927_CR2","first-page":"1125","volume":"191","author":"DL Panciera","year":"1987","unstructured":"Panciera DL, Bevier D. Management of cryptococcosis and toxic epidermal necrolysis in a dog. J Am Vet Med Assoc. 1987;191:1125\u20137.","journal-title":"J Am Vet Med Assoc"},{"key":"2927_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1751-0813.1996.tb13776.x","volume":"74","author":"R Malik","year":"1996","unstructured":"Malik R, Medeiros C, Wigney DI, Love DN. Suspected drug eruption in seven dogs during administration of flucytosine. Aust Vet J. 1996;74:285\u20138.","journal-title":"Aust Vet J"},{"key":"2927_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1751-0813.1996.tb10003.x","volume":"73","author":"R Malik","year":"1996","unstructured":"Malik R, Craig AJ, Wigney DI, Martin P, Love DN. Combination chemotherapy of canine and feline cryptococcosis using subcutaneously administered amphotericin B. Aust Vet J. 1996;73:124\u20138.","journal-title":"Aust Vet J"},{"key":"2927_CR5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/sj.gt.3302295","volume":"11","author":"NK Green","year":"2004","unstructured":"Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11:1256\u201363.","journal-title":"Gene Ther"},{"key":"2927_CR6","first-page":"424","volume":"7","author":"JM Benson","year":"1988","unstructured":"Benson JM, Nahata MC. Clinical use of systemic antifungal agents. Clin Pharm. 1988;7:424\u201338.","journal-title":"Clin Pharm."},{"key":"2927_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000007260","volume":"46","author":"A Vermes","year":"2000","unstructured":"Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy. 2000;46:86\u201394.","journal-title":"Chemotherapy"},{"key":"2927_CR8","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1001\/jama.1974.03230370055027","volume":"228","author":"R Meyer","year":"1974","unstructured":"Meyer R, Axelrod JL. Fatal aplastic anemia resulting from flucytosine. JAMA. 1974;228:1573.","journal-title":"JAMA"},{"key":"2927_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1128\/AAC.11.2.244","volume":"11","author":"CA Kauffman","year":"1977","unstructured":"Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977;11:244\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"2927_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1056\/NEJM197907193010303","volume":"301","author":"JE Bennett","year":"1979","unstructured":"Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301:126\u201331.","journal-title":"N Engl J Med"},{"key":"2927_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/infdis\/132.4.368","volume":"132","author":"JP Utz","year":"1975","unstructured":"Utz JP, Garriques IL, Sande MA, Warner JF, Mandell GL, McGehee RF, et al. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis. 1975;132:368\u201373.","journal-title":"J Infect Dis"},{"key":"2927_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jac\/46.2.171","volume":"46","author":"A Vermes","year":"2000","unstructured":"Vermes A. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46:171\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"2927_CR13","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1128\/AAC.14.6.903","volume":"14","author":"RB Diasio","year":"1978","unstructured":"Diasio RB, Lakings DE, Bennett JE. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother. 1978;14:903\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2927_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1128\/AAC.29.1.44","volume":"29","author":"BE Harris","year":"1986","unstructured":"Harris BE, Manning BW, Federle TW, Diasio RB. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother. 1986;29:44\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2927_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/BF01643246","volume":"19","author":"M-C Malet-Martino","year":"1991","unstructured":"Malet-Martino M-C, Martino R, de Forni M, Andremont A, Hartmann O, Armand JP. Flucytosine conversion to fluorouracil in humans: does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection. 1991;19:178\u201380.","journal-title":"Infection"},{"key":"2927_CR16","doi-asserted-by":"publisher","first-page":"9802","DOI":"10.1016\/S0021-9258(19)68695-3","volume":"256","author":"DW Kufe","year":"1981","unstructured":"Kufe DW, Major PP. 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem. 1981;256:9802\u20135.","journal-title":"J Biol Chem"},{"key":"2927_CR17","doi-asserted-by":"publisher","first-page":"8885","DOI":"10.1016\/S0021-9258(19)52479-6","volume":"256","author":"DW Kufe","year":"1981","unstructured":"Kufe DW, Major PP, Egan EM, Loh E. 5-Fluoro-2\u2019-deoxyuridine incorporation in L1210 DNA. J Biol Chem. 1981;256:8885\u20138.","journal-title":"J Biol Chem"},{"key":"2927_CR18","first-page":"4132","volume":"41","author":"M Tanaka","year":"1981","unstructured":"Tanaka M, Yoshida S, Saneyoshi M, Yamaguchi T. Utilization of 5-fluoro-2\u2019-deoxyuridine triphosphate and 5-fluoro-2\u2019-deoxycytidine triphosphate in DNA synthesis by DNA polymerases alpha and beta from calf thymus. Cancer Res. 1981;41:4132\u20135.","journal-title":"Cancer Res"},{"key":"2927_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1021\/bi00700a012","volume":"13","author":"DV Santi","year":"1974","unstructured":"Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry. 1974;13:471\u201381.","journal-title":"Biochemistry"},{"key":"2927_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/vco.12426","volume":"16","author":"K Menard","year":"2018","unstructured":"Menard K, Flesner BK, Glahn A, Boudreaux B, Bryan JN. Concurrent 5-fluorouracil and carboplatin for the treatment of canine carcinomas. Vet Comp Oncol. 2018;16:590\u20135.","journal-title":"Vet Comp Oncol"},{"key":"2927_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1439-0442.2001.00336.x","volume":"48","author":"M Karayannopoulou","year":"2001","unstructured":"Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Adjuvant post-operative chemotherapy in bitches with mammary cancer. J Vet Med A Physiol Pathol Clin Med. 2001;48:85\u201396.","journal-title":"J Vet Med A Physiol Pathol Clin Med"},{"key":"2927_CR22","doi-asserted-by":"crossref","unstructured":"Stanclift RM, Gilson SD. Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. J Am Vet Med Assoc. 2004;225:1412\u20137, 1393.","DOI":"10.2460\/javma.2004.225.1412"},{"key":"2927_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1939-1676.1998.tb02147.x","volume":"12","author":"CJ Henry","year":"1998","unstructured":"Henry CJ, Brewer WG, Tyler JW, Brawner WR, Henderson RA, Hankes GH, et al. Survival in dogs with nasal adenocarcinoma: 64 cases (1981\u20131995). J Vet Intern Med. 1998;12:436\u20139.","journal-title":"J Vet Intern Med"},{"key":"2927_CR24","unstructured":"Plumb DC. Plumb\u2019s veterinary drug handbook. 9th edition. Stockholm, Wisconsin: Pharma Vet Inc; 2018."},{"key":"2927_CR25","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/vco.12342","volume":"16","author":"B B\u00f8rresen","year":"2018","unstructured":"B\u00f8rresen B, Hansen AE, Kjaer A, Andresen TL, Kristensen AT. Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals. Vet Comp Oncol. 2018;16:E1\u201315.","journal-title":"Vet Comp Oncol"},{"key":"2927_CR26","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s11095-010-0233-4","volume":"27","author":"C Oerlemans","year":"2010","unstructured":"Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release. Pharm Res. 2010;27:2569\u201389.","journal-title":"Pharm Res"},{"key":"2927_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2217\/nnm.11.64","volume":"6","author":"A Tan","year":"2011","unstructured":"Tan A, Yildirimer L, Rajadas J, De La Pe\u00f1a H, Pastorin G, Seifalian A. Quantum dots and carbon nanotubes in oncology: a review on emerging theranostic applications in nanomedicine. Nanomed. 2011;6:1101\u201314.","journal-title":"Nanomed"},{"key":"2927_CR28","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3390\/molecules22122167","volume":"22","author":"K Zabielska-Koczyw\u0105s","year":"2017","unstructured":"Zabielska-Koczyw\u0105s K, Lechowski R. The use of liposomes and nanoparticles as drug delivery systems to improve cancer treatment in dogs and cats. Molecules. 2017;22:2167.","journal-title":"Molecules"},{"key":"2927_CR29","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.drudis.2020.06.006","volume":"25","author":"Y Alyassin","year":"2020","unstructured":"Alyassin Y, Sayed EG, Mehta P, Ruparelia K, Arshad MS, Rasekh M, et al. Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents. Drug Discov Today. 2020;25:1513\u201320.","journal-title":"Drug Discov Today"},{"key":"2927_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2019.03.005","volume":"14","author":"J Foloppe","year":"2019","unstructured":"Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, et al. The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism. Mol Ther Oncolytics. 2019;14:1\u201314.","journal-title":"Mol Ther Oncolytics"},{"key":"2927_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12917-020-02524-y","volume":"16","author":"J B\u00e9guin","year":"2020","unstructured":"B\u00e9guin J, Nourtier V, Gantzer M, Cochin S, Foloppe J, Balloul J-M, et al. Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs. BMC Vet Res. 2020;16:307.","journal-title":"BMC Vet Res"},{"key":"2927_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/0003-4819-80-5-613","volume":"80","author":"ER Block","year":"1974","unstructured":"Block ER. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance: studies in man. Ann Intern Med. 1974;80:613.","journal-title":"Ann Intern Med"},{"key":"2927_CR33","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1128\/AAC.01103-09","volume":"54","author":"MP Pai","year":"2010","unstructured":"Pai MP, Bruce H, Felton LA. Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. Antimicrob Agents Chemother. 2010;54:1237\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"2927_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/cpt1978243333","volume":"24","author":"RE Cutler","year":"1978","unstructured":"Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther. 1978;24:333\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"2927_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000221923","volume":"22","author":"A Polak","year":"1976","unstructured":"Polak A, Eschenhof E, Fernex M, Scholer HJ. Metabolic studies with 5-fluorocytosine-6-14\u00a0C in mouse, rat, rabbit, dog and man. Chemotherapy. 1976;22:137\u201353.","journal-title":"Chemotherapy"},{"key":"2927_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","volume":"83","author":"AM Stamm","year":"1987","unstructured":"Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83:236\u201342.","journal-title":"Am J Med"},{"key":"2927_CR37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/clind\/15.6.1003","volume":"15","author":"P Francis","year":"1992","unstructured":"Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992;15:1003\u201318.","journal-title":"Clin Infect Dis"},{"key":"2927_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/jof4040133","volume":"4","author":"N Spernovasilis","year":"2018","unstructured":"Spernovasilis N, Kofteridis D. Pre-existing liver disease and toxicity of antifungals. J Fungi. 2018;4:133.","journal-title":"J Fungi"},{"key":"2927_CR39","doi-asserted-by":"crossref","unstructured":"Patel R. Antifungal Agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc. 1998;73:1205\u201325.","DOI":"10.4065\/73.12.1205"},{"key":"2927_CR40","doi-asserted-by":"crossref","unstructured":"Sohail MA, Ikram U. Flucytosine-induced colitis. BMJ Case Rep. 2014;2014:1\u20133.","DOI":"10.1136\/bcr-2013-203381"},{"key":"2927_CR41","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0016-5085(82)80083-8","volume":"83","author":"CA White","year":"1982","unstructured":"White CA, Traube J. Ulcerating enteritis associated with flucytosine therapy. Gastroenterology. 1982;83:1127\u20139.","journal-title":"Gastroenterology"},{"key":"2927_CR42","first-page":"1187","volume":"59","author":"B Fond","year":"1983","unstructured":"Fond B, Bentata-Pessayre M, Krivitzky A, Callard P, Dupont B, Delzant G. Iatrogenic colitis during flucytosine treatment for neuromeningeal cryptococcosis. Sem Hopitaux Organe Fonde Par Assoc Enseign Med Hopitaux Paris. 1983;59:1187.","journal-title":"Sem Hopitaux Organe Fonde Par Assoc Enseign Med Hopitaux Paris"},{"key":"2927_CR43","first-page":"878","volume":"79","author":"WC Fortson","year":"1984","unstructured":"Fortson WC, Tedesco FJ. Drug-induced colitis: a review. Am J Gastroenterol. 1984;79:878\u201383.","journal-title":"Am J Gastroenterol"},{"key":"2927_CR44","first-page":"1684","volume":"88","author":"MS Cappell","year":"1993","unstructured":"Cappell MS, Simon T. Colonic toxicity of administered medications and chemicals. Am J Gastroenterol. 1993;88:1684\u201399.","journal-title":"Am J Gastroenterol"},{"key":"2927_CR45","volume-title":"Skin diseases of the dog and cat","year":"2005","unstructured":"Gross TL, Ihrke PJ, Walder EJ, Affolter VK, editors. Skin diseases of the dog and cat. Oxford, UK: Blackwell Science Ltd; 2005."},{"key":"2927_CR46","doi-asserted-by":"publisher","first-page":"256-e55","DOI":"10.1111\/vde.12217","volume":"26","author":"T Olivry","year":"2015","unstructured":"Olivry T, Rossi MA, Banovic F, Linder KE. Mucocutaneous lupus erythematosus in dogs (21 cases). Vet Dermatol. 2015;26:256-e55.","journal-title":"Vet Dermatol"},{"key":"2927_CR47","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/j.1939-1676.2012.00927.x","volume":"26","author":"KL Voie","year":"2012","unstructured":"Voie KL, Campbell KL, Lavergne SN. Drug hypersensitivity reactions targeting the skin in dogs and cats. J Vet Intern Med. 2012;26:863\u201374.","journal-title":"J Vet Intern Med"},{"key":"2927_CR48","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0738-081X(93)90167-B","volume":"11","author":"KV Mason","year":"1993","unstructured":"Mason KV. Blistering drug eruptions in animals. Clin Dermatol. 1993;11:567\u201374.","journal-title":"Clin Dermatol"},{"key":"2927_CR49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","volume":"78","author":"L Arnaud","year":"2019","unstructured":"Arnaud L, Mertz P, Gavand P-E, Martin T, Chasset F, Tebacher-Alt M, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019;78:504\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2927_CR50","first-page":"e613-615","volume":"29","author":"BM Almagro","year":"2011","unstructured":"Almagro BM, Steyls MC, Navarro NL, Dom\u00ednguez EG, Acosta EH, P\u00e9rez MAG, et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:e613-615.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2927_CR51","first-page":"3813","volume":"60","author":"P Erbs","year":"2000","unstructured":"Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase\/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000;60:3813\u201322.","journal-title":"Cancer Res"},{"key":"2927_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omto.2020.08.020","volume":"19","author":"J B\u00e9guin","year":"2020","unstructured":"B\u00e9guin J, Foloppe J, Maurey C, Laloy E, Hortelano J, Nourtier V, et al. Preclinical evaluation of the oncolytic vaccinia virus TG6002 by translational research on canine breast cancer. Mol Ther - Oncolytics. 2020; 19:57\u201366.","journal-title":"Mol Ther - Oncolytics"},{"key":"2927_CR53","unstructured":"Clinical Trials.gov. National Library of Medicine (US). Identifier NCT03724071, study of TG6002 (VV TK-RR-FCU1) in combination with 5-FC in patients with advanced gastro-intestinal tumors; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03724071."},{"key":"2927_CR54","unstructured":"Clinical Trials.gov. National Library of Medicine (US). Identifier NCT04194034, study of intrahepatic arterial infusion of TG6002 in combination with 5-FC in patients with metastatic colorectal cancer; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04194034."},{"key":"2927_CR55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/vco.283","volume":"14","author":"Veterinary cooperative oncology group","year":"2016","unstructured":"Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14:417\u201346.","journal-title":"Vet Comp Oncol"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02927-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-021-02927-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-021-02927-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T04:59:42Z","timestamp":1675486782000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-021-02927-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2927"],"URL":"https:\/\/doi.org\/10.1186\/s12917-021-02927-5","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with European legislation and French regulations on the protection of animals used for scientific purposes (Directive 2010\/63\/EU, 2010; Code rural, 2018; D\u00e9cret no. 2013\u2009\u2212\u2009118, 2013) and complied to the recommendations of the \u201cCharte nationale portant sur l\u2019\u00e9thique en exp\u00e9rimentation animale\u201d established by the \u201cComit\u00e9 National de R\u00e9flexion Ethique sur l\u2019Exp\u00e9rimentation Animale\u201d (CNREEA\u2014Minist\u00e8re de l\u2019Enseignement Sup\u00e9rieur, de la Recherche et de l\u2019Innovation\u2014Minist\u00e8re de l\u2019Agriculture et de l\u2019Alimentation). The study protocol was approved by the Anses\/EnvA\/UPEC ethical committee (N\u00b0 19\u2013047). Informed written consent to participate was required from the owners. Informed written consent was obtained from all dog owners.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.B., B.M., E.Q., and P.E. were employees of Transgene SA when the work was performed. Transgene SA is a publicly traded French biopharmaceutical company, with Institut Merieux as the major shareholder. The authors declare no other competing interests. J.B. is recipient of an Industrial Training Convention for Research (CIFRE) doctoral fellowship (2017\/0266). Other authors do not have any conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}